Pharmacological, Pharmacokinetic and Clinical Properties of Olopatadine Hydrochloride, a New Antiallergic Drug
Authors:
Open Access
- 1 January 2002
- journal article
- review article
- Published by Elsevier in The Japanese Journal of Pharmacology
- Vol. 88 (4) , 379-397
Abstract
Olopatadine hydrochloride (olopatadine, 11-[(Z)-3-(dimethylamino)propylidene]-6,11-dihydrodibenz[b,e]oxepin-2-acetic acid monohydrochloride) is a novel antiallergic/histamine H1-receptor antagonistic drug that was synthesized and evaluated in our laboratories. Oral administration of olopatadine at doses of 0.03 mg/kg or higher inhibited the symptoms of experimental allergic skin responses, rhinoconjunctivitis and bronchial asthma in sensitized guinea pigs and rats. Olopatadine is a selective histamine H1-receptor antagonist possessing inhibitory effects on the release of inflammatory lipid mediators such as leukotriene and thromboxane from human polymorphonuclear leukocytes and eosinophils. Olopatadine also inhibited the tachykininergic contraction in the guinea pig bronchi by prejunctional inhibition of peripheral sensory nerves. Olopatadine exerted no significant effects on action potential duration in isolated guinea pig ventricular myocytes, myocardium and human ether-a-go-go-related gene channel. Olopatadine was highly and rapidly absorbed in healthy human volunteers. The urinary excretion of olopatadine accounted for not less than 58% and the contribution of metabolism was considerably low in the clearance of olopatadine in humans. Olopatadine is one of the few renal clearance drugs in antiallergic drugs. Olopatadine was shown to be useful for the treatment of allergic rhinitis and chronic urticaria in double-blind clinical trials. Olopatadine was approved in Japan for the treatment of allergic rhinitis, chronic urticaria, eczema dermatitis, prurigo, pruritis cutaneous, psoriasis vulgaris and erythema exsudativum multiforme in December, 2000. Ophthalmic solution of olopatadine was also approved in the United States for the treatment of seasonal allergic conjunctivitis in December, 1996 (Appendix: also in the European Union, it was approved in February 2002).Keywords
This publication has 69 references indexed in Scilit:
- Olopatadine ophthalmic solution adjunctive to loratadine compared with loratadine alone in patients with active seasonal allergic conjunctivitis symptomsAnnals of Allergy, Asthma & Immunology, 2001
- Inhibitory effect of olopatadine hydrochloride (KW-4679), a novel antiallergic drug, on peptide leukotriene release from human eosinophilsAllergology International, 2001
- Evaluation of Olopatadine, a New Ophthalmic Antiallergic Agent with Dual Activity, Using the Conjunctival Allergen Challenge ModelAnnals of Allergy, Asthma & Immunology, 1998
- Inhibitory effects of terfenadine on the rising phase of action potentials and sinus rates in isolated guinea-pig myocardiumGeneral Pharmacology: The Vascular System, 1996
- Olopatadine (AL-4943A): Ligand Binding and Functional Studies on a Novel, Long Acting H1-Selective Histamine Antagonist and Anti-Allergic Agent for Use in Allergic ConjunctivitisJournal of Ocular Pharmacology and Therapeutics, 1996
- Biochemical properties of eosinophils and their preferential accumulation mechanism in nasal allergyJournal of Allergy and Clinical Immunology, 1994
- Site-Directed Mutagenesis of the Histamine H1 Receptor: Roles of Aspartic Acid107, Asparagine198 and Threonine194Biochemical and Biophysical Research Communications, 1994
- Effects of Topical Capsaicin on Autonomic Nerves in Experimentally-induced Nasal Hypersensitivity: An immunocytochemical studyActa Oto-Laryngologica, 1993
- Substance P as a potent stimulator of sneeze responses in experimental allergic rhinitis of guinea pigsInflammation Research, 1992
- A potent and selective non-peptide antagonist of the neurokinin a (NK2) receptorLife Sciences, 1992